This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified May 2017 by Tippi Mackenzie, University of California, San Francisco
Sponsor:
Information provided by (Responsible Party):
Tippi Mackenzie, University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT02986698
First received: December 5, 2016
Last updated: May 3, 2017
Last verified: May 2017
  Purpose
The investigators aims to evaluate the safety of in utero hematopoietic stem cell transplantation in fetuses with alpha-thalassemia major performed at the time of in utero transfusion of red blood cells.

Condition Intervention Phase
Alpha Thalassemia Major Hemoglobinopathy; With Thalassemia Hemoglobinopathies Fetal Anemia Fetal Hydrops Alpha; Thalassemia Thalassemia Major Thalassemia Alpha A-Thalassemia Biological: in utero hematopoietic stem cell transplantation Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-Center, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fetuses With Alpha Thalassemia Major

Resource links provided by NLM:


Further study details as provided by Tippi Mackenzie, University of California, San Francisco:

Primary Outcome Measures:
  • Maternal participant tolerance of bone marrow harvest [ Time Frame: 5 year recruitment phase to include time of bone marrow harvest through 30 days after delivery ]
    Maternal participant tolerance of bone marrow harvest defined as not requiring interventions for preterm labor, bleeding, infection or prolonged hospitalization.

  • Safety of in utero hematopoietic stem cell transplantation when performed at the same time as in utero blood transfusion for the fetal participant [ Time Frame: 5 year recruitment plus 1 year data collection phase to include time of IUHCT through 1 year after delivery ]
    safety for fetal participant defined by survival 24 hours after procedure, fetal survival till birth, neonatal survival through discharge of hospitalization and no evidence of graft versus host disease


Secondary Outcome Measures:
  • Adequate bone marrow harvest from the maternal participant [ Time Frame: 5 year recruitment phase ]
    This is defined as approximately 200-300 cc of bone marrow from which 10^7-10^9 CD34+ cells/kg fetal weight with 10^5-10^7 CD3+ cells/kg fetal weight will be isolated.

  • successful engraftment [ Time Frame: 5 year recruitment plus data collection phase to include time of IUHCT through 1 year after delivery ]
    The primary efficacy endpoint is successful engraftment of maternal bone marrow- derived CD34+ hematopoietic stem cells measured by establishment of maternal participant donor cell chimerism equal to or greater than 1% donor cells in the circulation of the fetal recipient. Chimerism will be determined in cord blood at birth, or at a corrected gestational age of 40 weeks, if there is preterm delivery, followed weekly for the first 4 weeks of life, and monthly for one year in the infant to monitor the stability of engraftment.


Estimated Enrollment: 10
Anticipated Study Start Date: July 2017
Estimated Study Completion Date: February 2024
Estimated Primary Completion Date: February 2022 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: in utero hematopoietic stem cell transplantation

Perform in utero hematopoietic stem cell transplantation at the time of intrauterine transplantation in fetuses with alpha-thalassemia major. The cellular product is: Semi-allogeneic, Related, Maternal Bone Marrow-Derived, Miltenyi CliniMACS Plus enriched CD34+ hematopoietic stem cells administered in utero at a dose of 1 x 10^7-10^9 cells/kg fetal weight with equal to or less than 1% CD3+ T cells (equivalent to 10^5-10^7 T cells/kg fetal weight) in a final volume of 2-5ml suspended in 5% human serum albumin in Normosol buffer (Hospira, Inc.).

Stem cells will be administered immediately before the red blood cells intravenously via the umbilical vein during the clinically indicated IUT. All participants will receive one dose of stem cells but may receive additional transfusions as clinically indicated.

Biological: in utero hematopoietic stem cell transplantation
This is a phase 1 safety study to demonstrate it is safe for both the mother and fetus to perform In utero hematopoietic stem cell transplantation of maternal derived stem cells at the time of intrauterine transplantation of red blood cells to treat fetuses affected with alpha-thalassemia major.

Detailed Description:

Alpha thalassemia major (ATM) is almost universally fatal in utero and represents an orphan disease with an unmet need for effective therapies. The only current treatment to allow the fetus to be born is to perform in utero transfusions (IUT) of red blood cells to treat the anemia and avoid the complications of hydrops and fetal demise. Often, affected pregnancies undergo elective termination after diagnosis. Cases with prenatal diagnosis of ATM who receive IUT and survive to birth will ultimately require lifelong monthly blood transfusions or bone marrow transplant, if a suitable donor is identified.

This is a phase 1 clinical trial to demonstrate the safety, feasibility and efficacy of performing in utero stem cell transplantation on fetuses affected with ATM. The investigators aim to recruit ten participants with a prenatal diagnosis of ATM. Participants will undergo bone marrow harvest and an in utero transfusion combined with maternal stem cells. Transplanting maternal cells into the fetus takes advantage of existing maternal-fetal tolerance during pregnancy. Hematopoietic stem cell (HSC) transplantation into the fetus takes advantage of the developing fetal immune system to induce tolerance to the transplanted cells without using conditioning or immunosuppression. Performing stem cell transplantation at the same time as IUT minimizes any additional procedural risk to the fetus.

The investigators hope to demonstrate that it is safe and feasible to perform in utero stem cell transplantation. Additionally, the investigators want to demonstrate postnatal chimerism of maternal cells so that, if a bone marrow transplant remains necessary after delivery, conditioning and immune suppression will not be required.

  Eligibility

Ages Eligible for Study:   18 Weeks to 25 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female fetuses from 18 weeks and 0/7 days to 25 weeks 0/7 days gestation with a diagnosis of alpha-thalassemia major by chorionic villus sampling (CVS), amniocentesis, cordocentesis or by identification of parents as genetic carriers, and identification of fetal anemia or signs of impending hydrops, for whom parents elect to pursue in utero transfusion, and are willing to undergo subsequent IUT for the remainder of gestation.
  • parents must consent to fetal autopsy in the event of a fetal demise
  • adequate bone marrow harvest from maternal participant is a condition for inclusion

Exclusion Criteria:

  • Fetal Subject Exclusion Criteria: Fetal participants will be excluded if they have a second major anatomic anomaly (not related to the underlying thalassemia) that contributes a significant morbidity or mortality risk, or echocardiogram or ultrasound findings that indicate a high risk of fetal demise after fetal intervention.
  • Maternal Subject Exclusion Criteria: Maternal participants will be excluded if they have one or more morbidities that would preclude bone marrow harvest and fetal intervention including, but not limited to, morbid obesity with BMI > 35, maternal cardiac disease, mirror syndrome, symptomatic maternal anemia, or if they develop preterm premature rupture of membranes (PPROM) or active preterm labor (PTL).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02986698

Contacts
Contact: Tippi Mackenzie, MD 415-476-4086 tippi.mackenzie@ucsf.edu
Contact: Billie Lianoglou, MS 415-476-1004 billie.lianoglou@ucsf.edu

Sponsors and Collaborators
University of California, San Francisco
Investigators
Principal Investigator: Tippi Mackenzie, MD University of California, San Francisco
  More Information

Publications:

Responsible Party: Tippi Mackenzie, Associate Professor of Surgery, University of California, San Francisco
ClinicalTrials.gov Identifier: NCT02986698     History of Changes
Other Study ID Numbers: 16-21157
Study First Received: December 5, 2016
Last Updated: May 3, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Tippi Mackenzie, University of California, San Francisco:
intrauterine transfusion
in utero human stem cell transplantation

Additional relevant MeSH terms:
Thalassemia
beta-Thalassemia
Hemoglobinopathies
alpha-Thalassemia
Hydrops Fetalis
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Genetic Diseases, Inborn
Erythroblastosis, Fetal
Fetal Diseases
Pregnancy Complications
Immune System Diseases
Edema
Signs and Symptoms

ClinicalTrials.gov processed this record on September 21, 2017